A "secret shopper" study found that 91.8% of websites selling GLP-1 medications issued a prescription without any real clinician involvement. Researchers say the prescription-centric model puts patients at risk of clinical and financial harm. Experts are calling on the FDA to step up oversight of these platforms.
A new "secret shopper" study published in JAMA reveals a troubling reality in the online GLP-1 marketplace: most websites hand out prescriptions with little to no meaningful clinical oversight. Researchers from Yale tested 49 websites selling GLP-1 receptor agonists and successfully obtained a prescription from 45 of them — often with nothing more than a questionnaire and an upper-body photo.
The findings raise serious red flags about patient safety. Half of the websites didn't ask about eating disorders (a key contraindication), only half inquired about diet and physical activity, and 75.6% charged patients and shipped medication without even asking for confirmation. Experts warn that clinicians on these platforms exist "in name, not in practice," turning a powerful chronic disease therapy into a transactional commodity.
Key Takeaways:
Why it matters: GLP-1s are among the most impactful therapies in modern medicine, but their rapid commercialization online is outpacing clinical standards. Without stronger regulatory oversight, patients risk receiving medications without proper screening, follow-up, or a genuine care plan.
